PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings • Assumptions PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Biosimilars: Overview • Comparative analysis of generic small molecules and biosimilars • Biosimilars market opportunities • Challenges for new entrants • Bio-betters PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Five forces analysis PART 07: Market segmentation by application • Global chronic and autoimmune diseases mAb biosimilars market • Global oncology mAb biosimilars market PART 08: Geographical segmentation • Global mAb biosimilars market by geographical segmentation 2015-2020 • mAb biosimilars market in Europe • mAb biosimilars market in Asia • mAb biosimilars market in rest of the world PART 09: Market drivers • Rise in number of patent expiries • Need for cost-effective treatment • Reimbursement benefits for biosimilars • Favorable government regulations PART 10: Impact of drivers PART 11: Market challenges • Physicians' reluctance to prescribe biosimilars • Multiple manufacturing complexities • Risks related to drug failure • Limited availability of biosimilar products • Difficulties in patient recruitment for clinical trials PART 12: Impact of drivers and challenges PART 13: Market trends • Emergence of biosimilars • Outsourcing of manufacturing activities • Need for high investment in R&D • High growth in the emerging markets • Rising number of strategic collaborations PART 14: Vendor landscape • Competitive scenario PART 15: Key vendor analysis • Biocon • Celltrion • Dr. Reddy's Laboratories • Hospira • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio

Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.